Cabiralizumab (Synonyms: FPA 008; Anti-Human CSF1R Recombinant Antibody) |
| Katalog-Nr.GC68820 |
Cabiralizumab (FPA 008) is a monoclonal antibody (MAb) against CSF1R. Cabiralizumab can enhance T cell infiltration and anti-tumor T cell immune response. Cabiralizumab inhibits osteoclast activation and prevents bone destruction, which can be used for research on rheumatoid arthritis (RA). Cabiralizumab can be combined with Nivolumab for lung cancer research.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1613144-80-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Review for Cabiralizumab
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for Cabiralizumab
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *